43 search results for: asthma

expert video

ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?

12 min

Pulmonology

Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss disease modification in severe asthma, including what disease modification is, how it can be identified, and how the advent of biologics may bring about disease modification.

expert video

Dr. Giorgio Canonica Regarding Multidisciplinary Approach

2 min

Rhinology

This video clip from the EAACI 2024 symposium highlights that a multidisciplinary approach is essential for the treatment of asthma.

expert video

ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?

30 min

Pulmonology

Professor Klaus Rabe shares a patient case highlighting the burden of disease associated with airway remodeling and discusses practical aspects of identifying and managing airway remodeling in severe asthma patients with Professor Porsbjerg and Dr Castro.

Infographic

Blood Eosinophils: A Biomarker in COPD

14 min

Pulmonology

In COPD, blood eosinophil testing is one of the five core assessments for initial patient evaluation, according to the GOLD Report. This infographic illustrates the role that blood eosinophils, as a biomarker for type 2 inflammation, play in predicting exacerbation risk and other COPD outcomes, and provides information from the GOLD Report on when to test for blood eosinophils and how eosinophils may guide patient management.

Podcast

ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases

15 min

Type 2 Inflammation

Profs. Klaus Rabe and Stephan Weidinger discuss shared and unique features of type 2 inflammatory diseases and the benefits of multidisciplinary care

Infographic

The Role of Type 2 Inflammation in Multiple Disease Trajectories

5 min

Dermatology

How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.

expert video

What proportion of patients can achieve control in CRSwNP?

5 min

Rhinology

Join Prof. Hellings and Prof. Corso in dicussion on the factors affecting complete control of CRSwNP, including treatment types, comorbidities, and the need for more data on biologics.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Dominican RepublicChange country/region